Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639003 | 0.97 | CYP19A1 (0.42) | CYP19A1CYP11B2PTGS2ESR1GPR84 | |
| SCHEMBL16231505 | 0.90 | ESR1 (0.36) | CYP19A1CYP11B2PTGS2ESR1ALOX5 | |
| SCHEMBL76484 | 0.87 | CYP19A1 (0.53) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL29416717 | 0.87 | CYP19A1 (0.53) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL13656641 | 0.86 | CYP19A1 (0.35) | CYP19A1CYP11B2PTGS2ESR1GPR84 | |
| SCHEMBL987188 | 0.86 | ALOX5 (0.47) | CYP19A1CYP11B2PTGS2ESR1GPR84 | |
| SCHEMBL4826058 | 0.86 | CYP19A1 (0.52) | CYP19A1CYP11B2PTGS2ESR1ESR2 | |
| SCHEMBL13511074 | 0.86 | CYP19A1 (0.36) | CYP19A1CYP11B2PTGS2ESR1RELA | |
| SCHEMBL13656643 | 0.85 | CYP19A1 (0.34) | CYP19A1CYP11B2PTGS2ESR1GPR84 | |
| SCHEMBL2086861 | 0.84 | CYP19A1 (0.44) | CYP19A1CYP11B2PTGS2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110049482-A1 | Novel aromatic compound and organic electroluminescent element containing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-7790892-B2 | Aromatic compound and organic electroluminescent element containing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20050214565-A1 | Novel aromatic compound and organic electroluminescent element containing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1496041-A1 | NOVEL AROMATIC COMPOUND AND ORGANIC ELECTROLUMINESCNET ELEMENT CONTAINING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110049482-A1 | Novel aromatic compound and organic electroluminescent element containing the same | TYR, EML4, TCF7L2 | CYP19A1 299/4885CYP11B2 1638/4885PTGS2 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.